The symptoms of UC are unpredictable. On a given day it can cause an urge to use the bathroom repeatedly, or blood in your ...

Key Takeaways Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ...

Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure. Mirikizumab treatment for 152 weeks is associated ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum with a relapsing–remitting course, has been a long and challenging journey, ...

Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of ...

Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

VELSIPITY is a sphingosine 1-phosphate receptor modulator prescription medicine indicated for the treatment of moderately to severely active ulcerative colitis in adults. VELSIPITY should not be ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...